Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 7, 2021-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participants have been dosed in the Phase 1/2...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials